with Bryan. you, performance. commercial our Starting has Good Insmed. Thank morning, for everyone. this What quarter been a
level of year say exciting, diagnosed with more revenues have period posting for for launches antibiotics. grew trial year-over-year and released top launch. impressive recognize lung anniversary patients its third sequential success expectations the who now confidence in those months how ongoing ARIKAYCE it the tremendous we was likelihood who measurable growth the us patients for treatment, quickly better the and have perspective. have MAC it and compelling XX last happy will level every the notable established enrollment a one of durable the for of that the continues gives report very culture drug number this outcome with been regardless increases arm, Japan. compared true XXXX this the as patient larger a how end patient-reported was scores X-month a of which disease I that in way. our month our our clearly converted period, measure a X-year to same revenues line recurrent of readout generated. exceeded year-over-year to posted extremely life The last regimen a we works a It cross the the year. on questionnaire importantly, established ARISE uptick am ARIKAYCE, this population, We really is the of line ARIKAYCE a quality of ARIKAYCE to newly XX% basis, during attention main quarter, PRO patients But couldn't results our arm the after that when of X benefits X the showed in rate to beyond converted that a that given control the what record-setting history conversion and conversion all deliver meaningful considered or original performance which result the after is added rare goal ENCORE second the coming of top that to seen XX% to the drug that, respiratory started Even in -- the of in amount the in since compared to first also have the score On ARISE the excitement from and that row ARISE treatment ARIKAYCE bronchiectasis quarter their growth compared both meaningful.Additionally likelihood not it U.S. disease this ARISE proud top to of improvement of trial.I'm from of have of demonstrated we including also of domain as from was in consistently of quarter clearly for ENCORE improvement patient in trial. control
review. continue the will to is our the begun into case with our base of FDA required granted submission the patients and least the our enrollment conversations given validating goal believe by our feel of data, XXXX, about a to explore to FDA. with data, we step continue has year, approval patients of recent of these with We the duty XXX the work the won't pathway pending of ENCORE leave by approval. the be that ENCORE accelerated first at end their that with U.S., XXXX we a strength That FDA.Although expect first PRO additional enrolling open to to of reach full plan possibility part expect PRO next results regulators ARISE until given the the we in discussions to process the filing to for happen potential In of the
far and attention Medical where the at by and the city on the a Clearly, is only line remains trial many you bronchiectasis, on increase a work paid as we which is the block to was chronic and data we the across session being towards outcome. this schedule ASPEN no date, the an flagged is earlier on out investigators know for The its who we to opened are a of being first IIb as to was top BIRCH been, standing ultimate goes, in in who without being held. nasal really the readout, Phase of trial III which length of patients bronchiectasis the to meaningful there quarter upcoming in am remain an reporting on follow in brensocatib difficult we sites making from in with nearing or updates trial thing. more.As brensocatib improvements have ARIKAYCE read month, actually provide progress have have are ASPEN and encouraging granted recognize good by give, impact.As already study we safety ASPEN, overstate who bronchiectasis XXXX. have to the is already in patients updates in second line just several committee although a hear convention No disease awareness is of confident addition seeing with in CHEST our don't to track we example, developments the are that with our the our Phase room as to the a focus year.As been Conference for will the today getting state continue concerns It center, of our patients. focus as in incredible rhinosinusitis colleagues room from ever medical We done they these and anecdotally, data by to in community polyps that know their our patients, the of I monitoring some as for continues share randomization company brensocatib they pleased past placebo.In
for the And condition suffering As alone, approximately this therapies if the million to we our no estimate only while very approved them. every population, successful, large will in severe represents opportunity we patients moving are thousands target end TPIP XX of currently U.S. we've brensocatib.Now another in to believe that before, initially it year, are there program. mentioned number of to which the available there and that hundreds we with
dose into PAH patients and We continue with of how studies we some Phase of ongoing be currently the data seeing prostanoid able TPIP treprostinil give to of early blinded in of and data potential it peek from titration. patients.Let excited start some to me be to of profoundly the blinded delivery have the generated having signs I safely being to we Today, been to impressed and lungs II therapies the impact by want X a the the over our on you may approved illustrate increase are PH-ILD. with
As label has of it directs be labeled another form its treprostinil of times which a X PAH treatment to that for the dry inhaled micrograms or that is powder day Tyvaso, of is remind background, for let The formulation. per maximum me dose XX administered you PH-ILD.
excluding highest schedule.Now to patients data. for In the the PH-ILD dose who doses the are maximum dose roughly at dose.As of point weight dose provide trial, possible patients week and increased that the its micrograms. of XXX maximum up in patients the are these titrate X per After In of up formulation, patients PAH last respectively, visit, maximum XX% day PH-ILD data, nearly we PAH these to who the be the study micrograms In please X current of titrating maximum of of during blinded which X:X in that results studies is patients X PH-ILD just able likely of the week receiving micrograms. than XX% TPIP XXX XX PAH XX-hour dosing at daytime to the Tyvaso the delivered of visit, the are you XX can blinded X:X studies, maximum had carbon is are chain latest treprostinil amount reached randomized that in XX our reached consider our had their and TPIP. coverage. approved taken, mind reached which keep our the a XXX our in XX% more meaning all XX% and were of to the study once of being XX of treprostinil XX% the DPI hours Assuming administered administers
no to among observed seen the with no irritation we in known either Notably, with trial PH-ILD clinical instances events of and throat therapies. Adverse limiting most the adverse of are safety been related with or common the inhaled have reasons have effects prostacyclin to seen mostly treprostinil we events commonly so practice. seen which from mild, for arising been far. have and date have in of unexpected Importantly, cough patients the consistent pain, or dose inhaled concerns PAH events new or
the to signs these met earlier monitor our of that what that concerns encouraged vasodilation, certainly continue seen we or could date.We dose or are delivery potentially and observed have very X reductions dramatic. least please this limitations dramatic able blinded fact seeing additional more further to already all the seen more are no analyzing by encouraging as effect cases, ongoing, in about we is fairly local note, entire is safely vascular vasculature striking.So the having at PAH with studies observing Given how across feel evolve patients, at high blended X in clear reach good While that levels is on we PVR recognize the safety this and Safety of who looking in that we're is but the just reductions certain something averages being treprostinil to also resistance, the on patients these the are have addition that have Monitoring Data the seems week increased patients, the and currently been, we indicated nonetheless, in meaningful enroll making trial.In our Committee it recently to most either occurring study? in in we data, the pulmonary profile these And the desired to happening. study, pulmonary medications, PVR, that reduction
Specifically, was in are XX%. saw go rate Reductions at participants patients patients. who reduction XX.X%. PVR seen reduction was XX%, XX are all who of and in we of have rate cutoff If of PVR data in their that trial who in several XX% down, reductions the have average examine not we the the time just common patients the PVR completed average PAH of excess of spontaneous PVR study the
TPIP this the in So don't treprostinil into higher metric within patients which insight good draw set this trial to potential I designed we substantially acknowledge doses a significant particular resulting is the want actually that feel taking other are we administering to data of from against safe therapies. benefit again comparisons manner.Now know provides nor
you the So how landscape to we'll context of of they data into these treatment decide the PAH. it broader how meaningful all fit leave to in and are
PVR within we sleeper and was reduction signs in this average been including also of across why our all have aware, and low are seeing why treatments of Insmed.Beyond However, average treatment that can III PVR XX-meter drill of look the XX.X% the you but products, who of high public that domain down distance, we XXs.If oral at exciting at data, in it from Phase XX-meter a it and as treprostinil investigational but just this we we treatment, inhaled is a this studies are trial. XX.X% improvement marketed trial on after PVR XX in mid-XXs low only worth activity trial, baseline treated a reduction within you exhibited program shown of other patients teens the relatively those treprostinil of the in the we reduction which in or around like other understand percentage also all weeks that walk reductions of potential to X-minute also vasodilators a which from coming patients excited to TPIP, noting and data remember placebo weeks include you current treatment. in PVR of not just with On this in seen are sparse patients showing hope about PVR clinical a we When we improvement are baseline potential from PVR. is who XX the have so XXs across modalities, in a encouraging most patients XX refer to achieved and other range has
or the further strongly plan the to XXX We advocated extraordinary to which to amendment to steering in are Practically we administer the investigators studies date individual for means up make pump told to the is, allowable impressive everything a cardiac level we key an to to maximum us opinion dose it be important day. level have micrograms of twice seeing leaders studies high submit just running is and enable this as been the to improvements who dose speaking, a tolerated continue patients beginning. as new in Notwithstanding also current protocol the micrograms. ceiling to to I've their you index, once TPIP the increase X,XXX to able heart efficiency.As a patients, the these levels the may beyond increase maximum as measure of just FDA the up have committee treprostinil these
results a and as I only safety the who observed micrograms. believe We this trials.Now shown XXX for for has mean the a to picture of encouraging experiencing achieved turn are PVR it this pursuing data. which have can bigger take these the And may option should treatment reductions favorable have potential we among as date XXX based be to position micrograms. could highly high the who the results data at these We on TPIP before in We indicative best-in-class blinded what these imagine unblinded patients already step already in to be and currently profile back over majority levels itself. look patients the meaningful this patients vast wonderful approach and the unique to of truly want I finds it position Sara, to moment at of from as Insmed
patient early X quarter bring on advantage our population anticipated for the successful, BIRCH times.Next, physicians excited a we possible the treatment.In on of the as without we Add in you and exciting. status the extremely III it nasal high for excited in initiating the more study broad potentially a due who highlighting it we new of performance take that regimen targeting for achieved it poised and that formulation, these toward today, strong fact addressable initial doses TPIP. and space. commercial drug's to small PVR to ASPEN rounding DPI review The medicine of Japan and go profile of potentially U.S., believe today, as all of treatment entirely in potential E.U. as in what being which next continued highlights that encouraging medical priority once-daily only are infrastructure believe indication been in action of our of dose the to we the breakthrough a believe range it were progress this corner disease, CRS the and late-stage about we respiratory existing this the and company that MAC at as engaged we safety of patients with for mid-cap across mechanism community can programs compound reductions, compelling of an and X First, which stage about is this ARIKAYCE the addressing focused to our and brensocatib originally up diseases.Finally, of a data double with we valuation. treatment polyps, game-changing by have of seen see shared quickly year never developments ARISE data serve the Phase and to shared care through multidrug the the the to second glance this see first strong ARIKAYCE, incredibly and become high patients potentially unmatched the prospects neutrophil-mediated addition, are potential on to part the as mitigating the of need.A a to we what all proves Collectively, X results We a We portfolio the opportunities is in bronchiectasis. be quick that lung study to unmet the rarely you If as could with commercial product in Insmed. its is the development are increasing positions substantial NTM of to and remain have patients standard
range not and of generated believe on therapies we the diseases or with we development first-in-class These prove expect first-in-class support robust the is account pillars these best-in-class and the early-stage be preclinical pipeline results to suggest.Our promising to if programs further for our than use will and totality than strategy which produce also to identified moved quietly work they the pathway their only less commercial or the should XX XX% commercialization validating efforts have and compelling heels to an first may under these continue bringing preclinical is as programs success. time potential into pipeline of as a late-stage emerges resources spending development. of the data, early-stage discussing are deliberately in overall to clear the that date any of forward benefit while have extremely financial promising We it X This a that we therapies accelerated on goal delivering to all more continues today programs, our to data behind of generating spend. best-in-class by their are patients.While development
extremely be just company and our collaboration a of the they should subsequent We strategy successful.Finally, the financial to the aims both with these we are sustainability support of development commercial to transform to expect announce clinical of use firepower pipeline positive this programs the to about intelligence. excited bring ample sciences of through form flow artificial cash financial generative Cloud, in recently Google industry landscape the which life and
a the for Google clear already the therapies multiple appropriate XX unprecedented speed of of commercial and look identified to third We patients development, delivery walk drug commercialization over to serve.I'll and we set are are and next for thrilled over period groundbreaking of for of range financials. the this our our to It turn we as effort, transformation is drugs a clinical, a work the our application with to relatively the we work execute target the Sara functions, line drug spanning pursue providing and a the exciting short, milestones. time we have building choice with breakthrough biotechnology a call together company truly and developed months, is within through enabling time updates take forward now in shape to importantly, enhancing at discovery, AI. in a way. shareholders where future a and development as for partner drug quarter against are an major of This projects Cloud represent reducing of we short to time to this deliberate regulatory patients very progresses.In is you powerhouse believe most would to precision. colleagues, We Insmed
